RHHBY - Roche Holding AG

Other OTC - Other OTC Delayed Price. Currency in USD
33.83
+0.07 (+0.21%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close33.76
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume1,276,935
Market Cap229.741B
Beta (3Y Monthly)0.43
PE Ratio (TTM)22.04
EPS (TTM)1.54
Earnings DateN/A
Forward Dividend & Yield1.07 (3.18%)
Ex-Dividend Date2019-03-07
1y Target Est35.55
Trade prices are not sourced from all markets
  • Ascendis Pivotal Growth Hormone Deficiency Study Data Positive
    Zacks14 hours ago

    Ascendis Pivotal Growth Hormone Deficiency Study Data Positive

    Ascendis Pharma's (ASND) growth hormone deficiency candidate fares better than Pfizer's Genotropin in improving annual rate for increase in height in children.

  • Benzinga17 hours ago

    What's Driving The Rally In Microcap Biotech Curis?

    Thinly traded Curis, Inc. (NASDAQ: CRIS ) shares weremoving notably higher Monday on roughly 35 times their average volume. What Happened Curis announced Monday ahead of the market open that it reached ...

  • J&J Files Application for Darzalex Label Expansion in Europe
    Zacks18 hours ago

    J&J Files Application for Darzalex Label Expansion in Europe

    J&J (JNJ) seeks an approval for Darzalex combo pertaining to the newly diagnosed, transplant-ineligible multiple myeloma patient population in the EU.

  • Biogen Stock Crashes on Termination of Alzheimer's Studies
    Zacks4 days ago

    Biogen Stock Crashes on Termination of Alzheimer's Studies

    Biogen (BIIB) and its Japanese partner, Eisai discontinue two late-stage studies evaluating aducanumab, in patients with Alzheimer's disease.

  • MarketWatch4 days ago

    Biogen stock downgraded to neutral from buy at UBS

    Analysts at UBS on Friday downgraded shares of Biogen Inc. to neutral from buy, while cutting their price target on the stock to $242 from $395. "The failure of aducanumab leaves Biogen with a lack of visibility around a path back to top-line growth, and increasingly present threats to the base-business that investors had been willing to look past given the promise of Alzheimer's," analysts led by Carter Gould wrote. He cited competition to spinal muscular atrophy drug Spinraza from Roche Holding's ridiplam and threats to a 2028 patent on the company's multiple sclerosis drug Tecfidera, which is under review by trademark officials after competitor Mylan N.V. filed a patent challenge in July. Biogen's stock, which fell 1.5% in premarket trade Friday, plunged 29% on Thursday after the company announced it would be discontinuing Phase 3 trials for aducanumab, its much-hyped Alzheimer's drug. Shares of the drugmaker have fallen 25% in the year to date, while the S&P 500 has gained 13.9%.

  • Is Biogen a Bad-News Buy Now?
    Motley Fool4 days ago

    Is Biogen a Bad-News Buy Now?

    Now that the riskiest asset in biotech is off the table, it's time to reconsider an industry legend that's down 30% on Thursday.

  • Roche sues U.S. executives in fight over diabetes test strips
    Reuters5 days ago

    Roche sues U.S. executives in fight over diabetes test strips

    Roche is seeking damages and compensation in a U.S. lawsuit against former executives of a Utah-based company, the Swiss drugmaker's latest case targeting what it calls fraudulent schemes involving its diabetes test strips. Roche has filed several lawsuits in U.S. federal court in which it alleges individuals and companies obtained low-priced diabetes test strips meant for mail-order customers, only to re-direct them for sale via pharmacies where higher prices allowed them to profit from the difference. "Defendants caused Roche to wrongfully pay over $87 million in rebates and to lose a similar amount of sales of retail strips," according to Roche's complaint filed in U.S. District Court in New Jersey on Tuesday against more than a dozen defendants including Jeffrey C. Smith, chief executive at Utah's Alliance Medical Holdings until 2017.

  • Bristol-Myers' Celgene Buyout Still Uncertain Amid Opposition
    Zacks5 days ago

    Bristol-Myers' Celgene Buyout Still Uncertain Amid Opposition

    The acquisition deal between Bristol-Myers and Celgene faces opposition from stakeholders of Bristol-Myers. The future of the deal depends on the outcome of the Special Meeting in April.

  • Barrons.com5 days ago

    Biogen Stock Is Plunging Because Its Alzheimer’s Treatment Failed

    Biogen stock lost more than a quarter of its value during premarket trading Thursday morning after the company announced it would discontinue trials of its Alzheimer’s disease drug. The stock, however, may not be a bargain yet.

  • InvestorPlace5 days ago

    Should You Buy Bio-Path Stock After 5-Fold Gain? 3 Pros, 3 Cons

    With so much attention pointing once again to the again-escalating U.S.-China trade dispute, it's easy to overlook Bio-Path Holdings (NASDAQ:BPTH). However, the oncology specialist is easily one of the best-performing investments of 2019. Year-to-date, BPTH stock has gained a mind-blowing near-500%.More importantly, a fundamental catalyst supports the dramatic rise in valuation. A favorable clinical trial of the company's acute myeloid leukemia drug lifted Bio-Path stock from the doldrums. This news has obvious positive implications, as this particular cancer has a market size of $701.6 million. Overall, leukemia's market value will likely hit $12 billion in a few years.At the same time, biotechnology firms are hardly stable investments. While BPTH stock currently enjoys the afterglow of a promising trial, it could just as easily go awry. After all, if cancer research was straightforward, we'd already have a cure.InvestorPlace - Stock Market News, Stock Advice & Trading TipsInvariably, though, the skyrocketing Bio-Path stock commands our attention. Should you buy into this winning streak, or is this hand destined to cool? Here are three pros and three cons to consider: Pro 1: A Possible Breakthrough Could Further Boost BPTH StockI'm not breaking new ground when I say that cancer is an uncomfortable subject. However, acute myeloid leukemia is a nasty strain. The disease spreads very rapidly if left untreated. By entering the bloodstream, this cancer can affect the liver, spleen, central nervous system, and testicles. * Top 7 Service Sector Stocks That Will Pay You to Own Them The latter may have caught the attention of Wall Street's men, who fueled the spike in BPTH stock.In all seriousness, though, the latest clinical trial offered encouraging data. Out of 17 patients in the study, 11 responded to Bio-Path's prexigebersen drug. And of those 11, five experienced a complete response. Pro 2: Bio-Path Stock Levers Profound TechnologiesA thousand years from now, I'm sure that our future progeny will look back on us with macabre fascination for how we treated cancer by blasting patients with radiation. I can't help but bring up the obvious question: doesn't radiation cause cancer?Fortunately, much smarter people than I have answered this inquiry. Bio-Path's solution is their proprietary DNAbilize platform. In short, this enables oncologists to precisely deliver cancer-killing therapies to affected cells without nuking the patient.Such technologies lever a broader impact on this industry. Some patients simply don't have the physical strength to endure chemotherapy or radiology. DNAbilize is a lifesaver on multiple fronts, further bolstering the case for Bio-Path stock. Pro 3: BPTH Probably Already Hit Rock-BottomI'm not always comfortable with the argument that a particular stock has priced in all the bad news. Unless you're privy to insider information -- at which point you shouldn't act on that info -- you just don't know if more nasty stuff lies ahead.However, I can't imagine BPTH stock falling even more than it already has. Bear in mind that shares used to trade for well over $500 just a few years ago. With that context, BPTH appears like a bargain, even with this year's mooning. Con 1: Shares Used to Trade at $500-plusOn one hand, the ability to buy Bio-Path stock for pennies on the dollar appeals to many contrarians. But those with a critical eye will argue that a reason exists for the meltdown.Let's look even further back. In early January 2014, BPTH stock was on the cusp of clearing $1,000. In May of 2008, and just prior to the Great Recession, it hit four digits.The argument that "it can't get any worse" failed these early investors "bigly." You don't want to repeat their mistake. Con 2: Bio-Path has Tough CompetitionWhile Bio-Path's DNAbilize platform appears profoundly impressive, it's not the only party in town. BPTH is riding the broader category of gene therapy, or the targeted delivery of disease-fighting therapies. But other names, including CRISPR Therapeutics (NASDAQ:CRSP), Roche Holding (OTCMKTS:RHHBY), and Editas Medicine (NASDAQ:EDIT) compete aggressively in this sector. * 5 Cloud Stocks to Help Your Portfolio Fly Given the historical volatility in BPTH stock, I want some reassuring factors that I can depend on. Unfortunately, Bio-Path doesn't have a moat, which makes me jittery about its sudden rise. Con 3: Biotech is Incredibly VolatileRight now, everyone has mad love for Bio-Path stock because of its unexpected ascent. However, I've seen this story play out before in this wild market segment. All it takes is one bad trial to undo years of effort and research.Plus, BPTH stock has two obstacles regarding its drug pipeline. Management must demonstrate that their therapies can consistently beat placebo, which is no easy task. Plus, they have to show that their solutions are superior to the competition. Again, that's no gimme. Bottom Line on BPTH StockAdmittedly, I see the both the technical and fundamental potential for BPTH, and I'm personally intrigued. However, I keep going back to the inherent volatility of the biotech industry and Bio-Path stock. Yes, it enjoyed a positive paradigm-shift, but it could just as easily go sour.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Invincible Stocks Leading The Bull Market Higher * 5 Dow Jones Stocks Coming to Life * 7 of the Best High-Yield Funds for 2019 and Beyond Compare Brokers The post Should You Buy Bio-Path Stock After 5-Fold Gain? 3 Pros, 3 Cons appeared first on InvestorPlace.

  • AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA
    Zacks6 days ago

    AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA

    FDA places a partial clinical hold on all studies evaluating AbbVie's (ABBV) Venclexta (venetoclax) for the treatment of multiple myeloma.

  • The Wall Street Journal6 days ago

    Pfizer Adds to Big Pharma's Gene-Therapy Deal Streak

    Inc. has agreed to pay up to €560 million ($636 million) for the rights to gene therapies under development at French company Vivet Therapeutics, as it seeks to build its pipeline in this cutting-edge treatment. The U.S. drugmaker said Wednesday it had paid €45 million upfront for a 15% stake in Vivet. Further payments, which include the potential acquisition of Vivet, are dependent on the progress of the French company’s experimental therapies.

  • Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia
    Zacks6 days ago

    Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia

    Puma Biotech (PBYI) gains an approval in Australia for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.

  • Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer
    Zacks7 days ago

    Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer

    Roche (RHHBY) gets an FDA approval of sBLA for Tecentriq in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).

  • Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead?
    Zacks7 days ago

    Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead?

    Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead?

  • Benzinga7 days ago

    The Daily Biotech Pulse: FDA Nod For Roche And Amphastar, Milestone Payment Kicks In For Affimed

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 18) AstraZeneca plc (NYSE: AZN )(received orphan drug ...

  • Can Dermira Stock Keep Soaring?
    Motley Fool7 days ago

    Can Dermira Stock Keep Soaring?

    The skincare specialist's experimental eczema treatment hit the mark in mid-stage testing, but what about the road ahead?

  • GlobeNewswire7 days ago

    FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer

    OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).

  • Reuters7 days ago

    U.S. FDA approves Roche's small cell lung cancer treatment

    Swiss drugmaker Roche Holding AG's U.S. unit Genentech said on Monday its immunotherapy Tecentriq won approval for a tough-to-treat type of lung cancer, the latest win for the drug whose sales trail medicines from Merck & Co and Bristol-Myers Squibb. The U.S. Food and Drug Administration (FDA) approved Tecentriq plus chemotherapy for untreated extensive-stage small cell lung cancer (SCLC), after a study showed patients getting the drug cocktail lived a median 12.3 months, compared to 10.3 months for those getting chemotherapy alone, Genentech said in a statement.

  • Business Wire7 days ago

    FDA Approves Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Adults With Extensive-Stage Small Cell Lung Cancer

    OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).

  • Starbucks touts its delivery & upgraded rewards programs
    Yahoo Finance Video5 days ago

    Starbucks touts its delivery & upgraded rewards programs

    Starbucks invited investors its hometown of Seattle today. CEO Kevin Johnson spoke with Yahoo Finance's Julia La Roche about the coffee giant's delivery program and its decision to do a better job of rewarding its most loyal customers.

  • Starbucks CEO talks business outlook and tech investment
    Yahoo Finance Video6 days ago

    Starbucks CEO talks business outlook and tech investment

    Starbucks CEO Kevin Johnson sat down with Yahoo Finance reporter Julia La Roche to discuss the company's outlook and its recent $100 million private equity investment at the company's annual shareholder meeting in Seattle, WA.

  • Former Aetna CEO on being a "radical capitalist" and the current state of health care
    Yahoo Finance Video7 days ago

    Former Aetna CEO on being a "radical capitalist" and the current state of health care

    Former Aetna CEO Mark Bertolini spent 8 years as company head until 2018 when the insurance giant was sold to CVS. He joins Yahoo Finance's Adam Shapiro, Julie Hyman, and Julia La Roche to discuss his new memoir "Mission-Driving Leadership: My Journey As A Radical Capitalist."

  • Starbucks is making a big change to its rewards program
    Yahoo Finance Video7 days ago

    Starbucks is making a big change to its rewards program

    Changes are coming to the Starbucks reward program, making it easier to get a free cup of coffee. Yahoo Finance’s Alexis Christoforous and Julia La Roche have details.